PTSD News

The COVID-19 pandemic had a great impact on the health care system and the well-being of health care professionals, the effects of which are still felt today.

There are two FDA-approved medications for PTSD, both selective serotonin reuptake inhibitors. The FDA has not approved a new medication for PTSD since 2001.

Individuals with type 2 diabetes who experience trauma may be at a lower risk for microvascular complications after resolving PTSD symptoms, according to a results from a retrospective study of U.S. veterans published in JAMA Network Open.

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

The FDA on Aug. 9 issued a complete response letter to Lycos Therapeutics for its new drug application regarding midomafetamine capsules for the treatment of PTSD, citing insufficient data to approve and requesting an additional phase 3 trial.

NEW YORK — In this Healio Video Perspective, Reid Robison, MD, MBA, senior principal investigator at Numinus, a company that conducts clinical trials in psychedelics, discusses promising new treatment options for psychiatric conditions.

Since the launch of the 988 Suicide & Crisis Lifeline in 2022, counselors have answered more than 10 million calls, texts and chats from people seeking help for suicidal thoughts and mental health crises, according to HHS officials.

The FDA has accepted a supplemental new drug application from Otsuka and Lundbeck for Rexulti in combination with sertraline to treat adults with PTSD.

Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.